Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.

Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC.

JAMA. 2001 Jun 27;285(24):3107-15. Erratum in: JAMA 2001 Sep 5;286(9):1026.

PMID:
11427139
2.
3.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

4.

Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.

Mandelblatt JS, Lawrence WF, Gaffikin L, Limpahayom KK, Lumbiganon P, Warakamin S, King J, Yi B, Ringers P, Blumenthal PD.

J Natl Cancer Inst. 2002 Oct 2;94(19):1469-83.

PMID:
12359856
5.

Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.

Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C.

Gynecol Oncol. 2009 Feb;112(2):377-83. doi: 10.1016/j.ygyno.2008.08.030. Epub 2008 Dec 11.

PMID:
19081611
6.
7.

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

Kim JJ, Wright TC, Goldie SJ.

J Natl Cancer Inst. 2005 Jun 15;97(12):888-95.

PMID:
15956650
8.

Cost-effectiveness of cervical-cancer screening in five developing countries.

Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, Wright TC; Alliance for Cervical Cancer Prevention Cost Working Group..

N Engl J Med. 2005 Nov 17;353(20):2158-68.

9.

Benefits and costs of using HPV testing to screen for cervical cancer.

Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K.

JAMA. 2002 May 8;287(18):2372-81.

PMID:
11988058
10.

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group..

J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.

PMID:
16418511
11.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

12.

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.

Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.

BJOG. 2012 Jan;119(2):166-76. doi: 10.1111/j.1471-0528.2011.02974.x. Epub 2011 Apr 12.

13.

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ.

J Natl Cancer Inst. 2008 Mar 5;100(5):308-20. doi: 10.1093/jnci/djn019. Epub 2008 Feb 26.

14.

Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.

Lince-Deroche N, Phiri J, Michelow P, Smith JS, Firnhaber C.

PLoS One. 2015 Nov 16;10(11):e0141969. doi: 10.1371/journal.pone.0141969. eCollection 2015.

15.

Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.

Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P.

Can J Public Health. 2010 May-Jun;101(3):220-5.

PMID:
20737813
16.

[Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment].

Zhao FH, Chen JF, Gao XH, Gao LM, Liu QG, Liu ZH, Xu H, Ma JF, Ma L, Xu XL, Hu SY, Ning Y, Shi JF, Qiao YL.

Zhonghua Zhong Liu Za Zhi. 2012 Aug;34(8):632-6. doi: 10.3760/cma.j.issn.0253-3766.2012.08.017. Chinese.

PMID:
23159002
17.
18.

Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.

Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V.

Pharmacoeconomics. 2011 Sep;29(9):781-806. doi: 10.2165/11586560-000000000-00000.

PMID:
21838332
19.

Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.

Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK.

Gynecol Oncol. 2010 Nov;119(2):237-42. doi: 10.1016/j.ygyno.2010.07.004. Epub 2010 Aug 14.

20.

Human papillomavirus DNA testing for cervical cancer screening in low-resource settings.

Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC.

J Natl Cancer Inst. 2000 May 17;92(10):818-25.

PMID:
10814677

Supplemental Content

Support Center